INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Indero is heading to Orlando, Florida for the AAD and DIF annual meetings!

Indero

Indero

Team of Experts

Author picture

We are thrilled to announce our participation in two major events in Orlando this March. These events are not to be missed, as we will have some groundbreaking news to share!

1. American Academy of Dermatology (AAD) Annual Meeting (March 7-11)

We will once again be exhibiting at the AAD. Visit us at Booth #1061 to learn more about our full portfolio and how we can help you achieve your research goals. This is a fantastic opportunity to connect with our experts and explore new cutting-edge solutions together.

2. Dermatology Innovation Forum (DIF) (March 6)

We are proud to continue our long-standing sponsorship of the DIF, organized by Advancing Innovation in Dermatology (AID). This event is a hub for the latest advancements in dermatology, and we are excited to be part of it once again.

Don’t Miss Our Big Announcement!

We have been working on something truly groundbreaking, and we can’t wait to reveal it at these events. Be sure to book a meeting with us to get an exclusive first look at our exciting announcement.

We look forward to seeing you in Orlando!

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >